Pharmacovigilance risk management plans


Risk management plan explains the knowledge about the safety and efficacy of a medicinal product. The RMP gives information on plans for studies and other activities to gain knowledge on the safety and efficacy of the medicine. It also describes measures to be undertaken to minimise risks associated with the use of product in patients. Marketing authorisation holders are required to have an RMP for any new medicinal product for human use that must be submitted at the time of application for marketing authorisation. For nationally authorised products RMPs must be submitted for review and approval.


  • Risk Minimisation Measures
  • Safety communications
  • Marketing authorisation

Related Conference of Pharmacovigilance risk management plans

November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
December 01-02, 2025

13th International Conference on Clinical Trials

Vancouver, Canada
January 29-30, 2026

19th World Drug Delivery Summit

Paris, France
February 10-11, 2026

40th World Congress on Pharmacology and Therapeutics

Barcelona, Spain
February 23-24, 2026

3rd World Congress on Biologics and Biosimilars

London, UK
March 23-24, 2026

36th Annual European Pharma Congress

London, UK
March 24-25, 2026

11th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
April 16-17, 2026

19th European Biosimilars Congress

Rome, Italy
April 27-28, 2026

9th European Biopharma Congress

Paris, Aland Islands
May 28-29, 2026

3rd International Conference on Pharmacognosy

Madrid, Spain
July 27-28, 2026

39th World Congress on Pharmacology

Rome, Italy

Pharmacovigilance risk management plans Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in